NASDAQ:ABAX

Abaxis Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$83.00
0.00 (0.00 %)
(As of 08/1/2018)
Add
Compare
Today's Range
$83.00
Now: $83.00
$83.00
50-Day Range N/A
52-Week Range
$43.66
Now: $83.00
$83.98
VolumeN/A
Average Volume167,754 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
Abaxis logo

Industry, Sector and Symbol

Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Headlines

Will Zoetis' Acquisition Spree Pay Off?
March 13, 2021 |  nasdaq.com
See More Headlines

MarketRank

Overall MarketRank

0.75 out of 5 stars

Medical Sector

1226th out of 2,024 stocks

Measuring & Controlling Devices, Not Elsewhere Classified Industry

8th out of 19 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Receive ABAX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abaxis (NASDAQ:ABAX) Frequently Asked Questions

What stocks does MarketBeat like better than Abaxis?

Wall Street analysts have given Abaxis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abaxis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Abaxis' earnings last quarter?

Abaxis, Inc. (NASDAQ:ABAX) announced its earnings results on Thursday, April, 26th. The medical research company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.32 by $0.10. The medical research company had revenue of $67.90 million for the quarter, compared to the consensus estimate of $66.02 million. The business's quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.33 EPS.
View Abaxis' earnings history
.

Is Abaxis a good dividend stock?

Abaxis pays an annual dividend of $0.72 per share and currently has a dividend yield of 0.00%.
View Abaxis' dividend history.

Who are Abaxis' key executives?

Abaxis' management team includes the following people:
  • Mr. Clinton H. Severson, Chairman & CEO (Age 70)
  • Mr. Donald P. Wood, Pres & COO (Age 66)
  • Mr. Ross Taylor Jr., CFO, VP of Fin. & Sec. (Age 55)
  • Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
  • Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)

Who are some of Abaxis' key competitors?

What other stocks do shareholders of Abaxis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abaxis investors own include Skyworks Solutions (SWKS), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Allergan (AGN), Akorn (AKRX), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Amicus Therapeutics (FOLD), JetBlue Airways (JBLU) and Mylan (MYL).

What is Abaxis' stock symbol?

Abaxis trades on the NASDAQ under the ticker symbol "ABAX."

What is Abaxis' stock price today?

One share of ABAX stock can currently be purchased for approximately $83.00.

What is Abaxis' official website?

The official website for Abaxis is www.abaxis.com.

Where are Abaxis' headquarters?

Abaxis is headquartered at 3240 WHIPPLE ROAD, UNION CITY CA, 94587.

How can I contact Abaxis?

Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.